Hoda S. El Saeed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hoda S. El Saeed has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Areej Rushdi
Department of Medical Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11651, Egypt
2 shared publications - Ayman Abo Elmaaty
Medicinal Chemistry Department, Faculty of Pharmacy Port Said University Port Said Egypt
2 shared publications - Azza Ali Althoqapy
Department of Medical Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11651, Egypt
2 shared publications - Marwa Ahmed Saleh
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11651, Egypt
2 shared publications - Rogy R. Ezz Eldin
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said 42526, Egypt
2 shared publications Sefat A. Alwarsh
Department of Science, Prince Sultan Military College of Health Sciences, Dhahran 31932, Saudi Arabia
2 shared publications
Latest Publications
- Open Access
- 7 February 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 226
RETRACTED: Ezz Eldin et al. Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies. Pharmaceuticals 2023, 16, 1247
The Pharmaceuticals Editorial Office retracts the article “Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies”
- 7 February 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 226
Open AccessRETRACTED: Ezz Eldin et al. Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies. Pharmaceuticals 2023, 16, 1247
The Pharmaceuticals Editorial Office retracts the article “Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies”
- Open Access
- 4 September 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1247
RETRACTED: Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies
Herein, a series of new isatin derivatives was designed and synthesized (1–9) as broad-spectrum antiviral agents. Consequently, the antiviral activities of the synthesized compounds (1–9) were pursued against three viruses, namely influenza virus (H1N1), herpes simplex virus 1 (HSV-1), and coxsackievirus B3 (COX-B3). In particular, compounds 9, 5, and 4 displayed the highest antiviral activity against H1N1, HSV-1, and COX-B3 with IC50 values of 0.0027, 0.0022, and 0.0092 µM, respectively. Compound 7 was the safest, with a CC50 value of 315,578.68 µM. Moreover, a quantitative PCR (real-time PCR) assay was carried out for the most relevant compounds. The selected compounds exhibited a decrease in viral gene expression. Additionally, the conducted in silico studies emphasized the binding affinities of the synthesized compounds and their reliable pharmacokinetic properties as well. Finally, a structure–antiviral activity relationship study was conducted to anticipate the antiviral activity change upon future structural modification.
- 4 September 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1247
Open AccessRETRACTED: Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies
Herein, a series of new isatin derivatives was designed and synthesized (1–9) as broad-spectrum antiviral agents. Consequently, the antiviral activities of the synthesized compounds (1–9) were pursued against three viruses, namely influenza virus (H1N1), herpes simplex virus 1 (HSV-1), and coxsackievirus B3 (COX-B3). In particular, compounds 9, 5, and 4 displayed the highest antiviral activity against H1N1, HSV-1, and COX-B3 with IC50 values of 0.0027, 0.0022, and 0.0092 µM, respectively. Compound 7 was the safest, with a CC50 value of 315,578.68 µM. Moreover, a quantitative PCR (real-time PCR) assay was carried out for the most relevant compounds. The selected compounds exhibited a decrease in viral gene expression. Additionally, the conducted in silico studies emphasized the binding affinities of the synthesized compounds and their reliable pharmacokinetic properties as well. Finally, a structure–antiviral activity relationship study was conducted to anticipate the antiviral activity change upon future structural modification.